Tiffany Dernies

Suggest Changes
Learn More
AIM Cisplatin doublets are standard 1st line treatment for advanced non-small cell lung cancer (NSCLC), without accurate predictor for response and survival, but important toxicity. Our aims were to(More)
  • 1